Rahim A, Toogood A A, Shalet S M
Department of Endocrinology, Christie Hospital, Manchester, UK.
Clin Endocrinol (Oxf). 1996 Nov;45(5):557-62. doi: 10.1046/j.1365-2265.1996.00855.x.
In adults, there are few data regarding GH responses to provocative stimuli other than insulin-induced hypoglycaemia. We have compared the GH response to four different growth hormone secretagogues and placebo in normal healthy adult males.
This was a prospective, randomized, placebo-controlled study in 18 normal male subjects. After an overnight last, an intravenous cannula was inserted into the arm of each subject and a blood sample was taken for GH at -30, -15, and 0 minutes. Four provocative agents (intravenous insulin 0.2 IU/kg; intravenous arginine 20 g/m2 as an infusion over 30 minutes; oral clonidine, either 100 or 200 micrograms; intramuscular glucagon 1 mg) and placebo were administered to each subject in a randomized manner on different days. Further blood samples were taken at 15-minute intervals for 180 minutes for GH estimation.
The median (range) GH peak response for each agent was insulin 107.7 (28.1-200) mU/l; arginine 22.3 (3.1-72.9) mU/l; glucagon 42 (11.8-200) mU/l; 100 micrograms clonidine 7.2 (< 1-22.2) mU/l; 200 micrograms clonidine 8.2 (1.1- 88) mU/l and placebo 2.4 (< 1-30.2) mU/l. The peak GH response to insulin-induced hypoglycaemia (ITT) was significantly greater than for any other agent (P < 0.0001). The peak GH response to glucagon was significantly greater than for arginine (P < 0.05), clonidine at 100 and 200 micrograms (P < 0.01) and placebo (P < 0.01). The peak GH response following administration of arginine was significantly greater than for clonidine 100 and 200 micrograms (P < 0.05), and placebo (P < 0.01). The peak GH response following clonidine 200 micrograms was not significantly greater than following clonidine 100 micrograms (P = 0.38) or placebo. On an individual basis two, six and 15 of 18 subjects failed to achieve a peak GH level of > 20 mU/l to glucagon, arginine and clonidine respectively. In complete contrast only one subject achieved a peak response of less than 40 mU/l (28.1 mU/l) to ITT.
The most profound GH release is seen after insulin-induced hypoglycaemia. Glucagon appears to be more effective at inducing GH release than arginine. Clonidine at a dose of 100 or 200 micrograms is no more effective than placebo.
在成年人中,除胰岛素诱发的低血糖外,关于生长激素(GH)对刺激性刺激的反应数据很少。我们比较了正常健康成年男性对四种不同生长激素促分泌素和安慰剂的GH反应。
这是一项针对18名正常男性受试者的前瞻性、随机、安慰剂对照研究。经过一夜禁食后,在每个受试者的手臂上插入静脉套管,并在-30、-15和0分钟采集血样检测GH。在不同日期,以随机方式给每个受试者施用四种刺激性药物(静脉注射胰岛素0.2 IU/kg;静脉注射精氨酸20 g/m²,30分钟内输注完毕;口服可乐定,100或200微克;肌肉注射胰高血糖素1 mg)和安慰剂。每隔15分钟采集血样,共采集180分钟以检测GH。
每种药物的GH峰值反应中位数(范围)为:胰岛素107.7(28.1 - 200)mU/l;精氨酸22.3(3.1 - 72.9)mU/l;胰高血糖素42(11.8 - 200)mU/l;100微克可乐定7.2(<1 - 22.2)mU/l;200微克可乐定8.2(1.1 - 88)mU/l;安慰剂2.4(<1 - 30.2)mU/l。胰岛素诱发低血糖(ITT)后的GH峰值反应显著大于其他任何药物(P < 0.0001)。胰高血糖素的GH峰值反应显著大于精氨酸(P < 0.05)、100和200微克可乐定(P < 0.01)以及安慰剂(P < 0.01)。精氨酸给药后的GH峰值反应显著大于100和200微克可乐定(P < 0.05)以及安慰剂(P < 0.01)。200微克可乐定后的GH峰值反应并不显著大于100微克可乐定(P = 0.38)或安慰剂。在个体水平上,18名受试者中分别有2名、6名和15名对胰高血糖素、精氨酸和可乐定未能达到>20 mU/l的GH峰值水平。完全相反的是,只有一名受试者对ITT的峰值反应小于40 mU/l(28.1 mU/l)。
胰岛素诱发低血糖后可见最显著的GH释放。胰高血糖素在诱导GH释放方面似乎比精氨酸更有效。100或200微克剂量的可乐定并不比安慰剂更有效。